Roche Holding : A tough H1 2020 publication which does not affect the outlook
>Lockdown limited recourse to healthcare - Roche surprised us negatively yesterday with its H1 2020 publication. While Q1 had essentially only experienced the positive impact of COVID-19 (PCR and Actemra tests), the second part of the half year was marked by a contraction in activity (with as much as -15% in May!). Lockdown measures clearly prevented patients from seeing their doctors, going to hospital or doing routine tests. Interim sales nevertheless continue to gr...Roche Holding is a healthcare company. Co. operates in two Divisions, Pharmaceuticals and Diagnostics. Co.'s pharmaceuticals division is comprised of two business segments Roche Pharmaceuticals and Chugai. Co.'s pharmaceuticals division provides therapies including Cotellic, in combination with Zelboraf for advanced melanoma, and Alecensa for a specific type of lung cancer. Co.'s diagnostics division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. Co.'s diagnostics division provides in vitro diagnostic tests, used by healthcare providers to screen, diagnose and monitor therapies.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.